Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45


Topical Review: Building Competency: Professional Skills for Pediatric Psychologists in Integrated Primary Care Settings.

Hoffses KW, Ramirez LY, Berdan L, Tunick R, Honaker SM, Meadows TJ, Shaffer L, Robins PM, Sturm L, Stancin T.

J Pediatr Psychol. 2016 Nov;41(10):1144-1160. Epub 2016 Aug 26. Review.


Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds.

Mentz RJ, Hernandez AF, Berdan LG, Rorick T, O'Brien EC, Ibarra JC, Curtis LH, Peterson ED.

Circulation. 2016 Mar 1;133(9):872-80. doi: 10.1161/CIRCULATIONAHA.115.019902. Review.


Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.


The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations.

Roe MT, Mahaffey KW, Ezekowitz JA, Alexander JH, Goodman SG, Hernandez A, Temple T, Berdan L, Califf RM, Harrington RA, Peterson ED, Armstrong PW.

Am Heart J. 2015 Jun;169(6):743-50. doi: 10.1016/j.ahj.2015.03.002. Epub 2015 Mar 10. Review.


Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.


A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.

Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA; INNOVATE-PCI Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):336-46. doi: 10.1161/CIRCINTERVENTIONS.111.964197. Epub 2012 May 29.


The first call from Dad.

Berdan MR, Berdan LG.

Am Heart J. 2011 Nov;162(5):832-5. doi: 10.1016/j.ahj.2011.10.006. No abstract available.


Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

Mahaffey KW, Wampole JL, Stebbins A, Berdan LG, McAfee D, Rorick TL, French JK, Kleiman NS, O'Connor CM, Cohen EA, Granger CB, Armstrong PW; APEX-AMI Investigators.

Contemp Clin Trials. 2011 Mar;32(2):178-87. doi: 10.1016/j.cct.2010.12.013. Epub 2011 Jan 8.


Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).

Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW.

Am J Cardiol. 2009 Nov 15;104(10):1330-5. doi: 10.1016/j.amjcard.2009.06.056. Epub 2009 Sep 25.


Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators.

N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30.


Predicting cardiac vagal regulation in early childhood from maternal-child relationship quality during toddlerhood.

Calkins SD, Graziano PA, Berdan LE, Keane SP, Degnan KA.

Dev Psychobiol. 2008 Dec;50(8):751-66. doi: 10.1002/dev.20344.


Temperament and externalizing behavior: social preference and perceived acceptance as protective factors.

Berdan LE, Keane SP, Calkins SD.

Dev Psychol. 2008 Jul;44(4):957-68. doi: 10.1037/0012-1649.44.4.957.


Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.

Tricoci P, Lokhnygina Y, Berdan LG, Steinhubl SR, Gulba DC, White HD, Kleiman NS, Aylward PE, Langer A, Califf RM, Ferguson JJ, Antman EM, Newby LK, Harrington RA, Goodman SG, Mahaffey KW.

Circulation. 2007 Dec 4;116(23):2669-77. Epub 2007 Nov 19.


Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ 3rd, Califf RM.

Am Heart J. 2006 Dec;152(6):1042-50. Erratum in: Am Heart J. 2007 Feb;153(2):327.


High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.

Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ 3rd, Califf RM; SYNERGY Trial Investigators.

JAMA. 2005 Nov 23;294(20):2594-600.


Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.

Mahaffey KW, Roe MT, Kilaru R, French JK, Alexander JH, Berdan LG, Van De Werf F, Simoons ML, Weaver WD, White HD, Lincoff AM, Kleiman NS, Topol EJ, Harrington RA.

Am J Cardiol. 2005 Jun 15;95(12):1404-8.


Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).

Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ.

Am Heart J. 2002 Dec;144(6):995-1002.


Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

Fernandes LS, Tcheng JE, O'Shea JC, Weiner B, Lorenz TJ, Pacchiana C, Berdan LG, Maresh KJ, Joseph D, Madan M, Mann T, Kilaru R, Hochman JS, Kleiman NS; ESPRIT investigators.

J Am Coll Cardiol. 2002 Sep 18;40(6):1085-91.


Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.

Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA.

Am Heart J. 2002 Feb;143(2):242-8.


Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study.

Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf RM; For the PURSUIT Investigators .

Curr Control Trials Cardiovasc Med. 2001 Jul 17;2(4):187-194.

Supplemental Content

Loading ...
Support Center